Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to ease dystonia symptoms

NCT ID NCT07304089

Symptom relief Sponsor: Vima Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 4 times

Summary

This phase 2 trial tests whether VIM0423, a combination of two drugs, can reduce symptoms of isolated dystonia (a movement disorder causing muscle spasms). About 100 adults aged 18-65 with dystonia in at least two body areas will receive either VIM0423 or a placebo. Researchers will measure changes in symptom severity, daily function, and quality of life over the study period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VIM0423 (a combination of two drugs: VMA-1001 and VMA-1002)
What this could lead to
If it works, this could point toward a new treatment option to ease dystonia symptoms and improve daily life.
What could go wrong
This is an early phase 2 trial with only 100 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be male or nonpregnant female between 18 and 70 years of age (inclusive) at Visit 1 (Screening). * The participant has a clinical diagnosis of isolated dystonia with symptoms consistent with dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee. * The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria. * The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dystonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dystonia dystonic disorder isolated dystonia Torticollis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dystonia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    38 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Vima Site #002

    RECRUITING

    Farmington Hills, Michigan, 48334, United States

    Contact Email: •••••@•••••

  • Vima Site #004

    RECRUITING

    Scottsdale, Arizona, 85258, United States

    Contact Email: •••••@•••••

  • Vima Site #005

    RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Email: •••••@•••••

  • Vima Site #006

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Email: •••••@•••••

  • Vima Site #007

    RECRUITING

    Olney, Maryland, 20832, United States

    Contact Email: •••••@•••••

  • Vima Site #008

    RECRUITING

    Miami, Florida, 33176, United States

    Contact Email: •••••@•••••

  • Vima Site #009

    RECRUITING

    Gainesville, Florida, 32608, United States

    Contact Email: •••••@•••••

  • Vima Site #011

    RECRUITING

    Richmond, Virginia, 23233, United States

    Contact Email: •••••@•••••

  • Vima Site #012

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Vima Site #013

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Vima Site #014

    RECRUITING

    Albuquerque, New Mexico, 87106, United States

    Contact Email: •••••@•••••

  • Vima Site #015

    RECRUITING

    Spokane, Washington, 99202, United States

    Contact Email: •••••@•••••

  • Vima Site #016

    RECRUITING

    Memphis, Tennessee, 38157, United States

    Contact Email: •••••@•••••

  • Vima Site #018

    RECRUITING

    New York, New York, 10019, United States

    Contact Email: •••••@•••••

  • Vima Site #019

    RECRUITING

    Denver, Colorado, 80113, United States

    Contact Email: •••••@•••••

  • Vima Site #020

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Email: •••••@•••••

  • Vima Site #021

    RECRUITING

    Charleston, South Carolina, 29425, United States

    Contact Email: •••••@•••••

  • Vima Site #023

    RECRUITING

    Kirkland, Washington, 98034, United States

    Contact Email: •••••@•••••

  • Vima Site #024

    RECRUITING

    New York, New York, 10021, United States

    Contact Email: •••••@•••••

  • Vima Site #025

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Email: •••••@•••••

  • Vima Site #026

    RECRUITING

    Georgetown, Texas, 78628, United States

    Contact Email: •••••@•••••

  • Vima Site #027

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Email: •••••@•••••

  • Vima Site #028

    RECRUITING

    Sun City, Arizona, 85351, United States

    Contact Email: •••••@•••••

  • Vima Site #029

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Email: •••••@•••••

  • Vima Site #030

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact Email: •••••@•••••

  • Vima Site #031

    RECRUITING

    Orlando, Florida, 32825, United States

    Contact Email: •••••@•••••

  • Vima Site #032

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Email: •••••@•••••

  • Vima Site #033

    RECRUITING

    Birmingham, Alabama, 35233, United States

    Contact Email: •••••@•••••

  • Vima Site #035

    RECRUITING

    Cincinnati, Ohio, 45212, United States

    Contact Email: •••••@•••••

  • Vima Site #036

    RECRUITING

    Rochester, New York, 14618, United States

    Contact Email: •••••@•••••

  • Vima Site #037

    RECRUITING

    East Lansing, Michigan, 48824, United States

    Contact Email: •••••@•••••

  • Vima Site #038

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

  • Vima Site #039

    RECRUITING

    Scottsdale, Arizona, 85251, United States

    Contact Email: •••••@•••••

  • Vima Site #040

    RECRUITING

    Fayetteville, North Carolina, 28304, United States

    Contact Email: •••••@•••••

  • Vima Site #041

    RECRUITING

    Overland Park, Kansas, 66211, United States

    Contact Email: •••••@•••••

  • Vima Site #042

    RECRUITING

    Irvine, California, 92614, United States

    Contact Email: •••••@•••••

  • Vima Site #043

    RECRUITING

    Baltimore, Maryland, 21237, United States

    Contact Email: •••••@•••••

  • Vima Site #055

    NOT_YET_RECRUITING

    Amherst, New York, 14226, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.